Cahill Represents BofA in Credit Facility for BioMarin
Date: 11/29/16
Cahill represented Bank of America, N.A. in connection with a $100,000,000 revolving credit agreement for BioMarin Pharmaceutical Inc., a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. Proceeds from the facility will be used for general corporate purposes.